ReviewProgress in cardiovascular diseases
Cardiovascular disease prevention and management in the COVID-19 era and beyond: An international perspective.
Review in Progress in cardiovascular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Personalized Nutrition Biomarkers and Dietary Strategies for Atherosclerosis Risk Management: A Systematic Review.Nutrients · 2025Pooled it
- Effectiveness of a respiratory rehabilitation program including an inspiration training devicePeerJ · 2023Trial
- A novel mechanistic insight: BYHWD glycosides promote vascular endothelial repair via EPCs.European journal of medical research · 2026Article
- Molecular Interplay between hypertension and dyslipidemia in cardiovascular pathogenesis: toward precision-based therapeutic strategies.Frontiers in cardiovascular medicine · 2026Review
- Integrating stent design and microstructural characterization to improve clinical outcomes of bioresorbable stents.Materials & design · 2025Article
- Article
- Review
- A Cross-talk between Nanomedicines and Cardiac Complications: Comprehensive View.Current pharmaceutical design · 2025Review
- Effect on consumers' sustainable purchase intention of dietary supplement purine labeling.Frontiers in nutrition · 2025Article
- The Complex Relationship Between Chronic Obstructive Pulmonary Disease With Cardiovascular Disease and Their Interactions With COVID-19 Vaccination: A Retrospective Study.Immunity, inflammation and disease · 2024Article
- Article
- Current Role and Future Perspectives of Cardiac Rehabilitation in Heart Disease.Reviews in cardiovascular medicine · 2024Review
- COVID-19-related cardiovascular disease risk due to weight gain: a nationwide cohort study.European journal of medical research · 2024Article
- Review
- Elucidating VSMC phenotypic transition mechanisms to bridge insights into cardiovascular disease implications.Frontiers in cardiovascular medicine · 2024Review
- Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.Frontiers of medicine · 2023Review
- Heart Sound Classification Network Based on Convolution and Transformer.Sensors (Basel, Switzerland) · 2023Article
- The COVID-19 Pandemic and Coronary Heart Disease: the Next Surge.Current atherosclerosis reports · 2023Review
- Hyperparameter optimization for cardiovascular disease data-driven prognostic system.Visual computing for industry, biomedicine, and art · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite some indicators of a localized curtailing of cardiovascular disease (CVD) prevalence, CVD remains one of the largest contributors to global morbidity and mortality. While the magnitude and impact of the coronavirus disease 2019 (COVID-19) pandemic have yet to be realized in its entirety, an unquestionable impact on global health and well-being is already clear. At a time when the global state of CVD is perilous, we provide a continental overview of prevalence data and initiatives that have positively influenced CVD outcomes. What is clear is that despite attempts to address the global burden of CVD, there remains a lack of collective thinking and approaches. Moving forward, a coordinated global infrastructure that, if developed with appropriate and relevant key stakeholders, could provide significant and longstanding benefits to public health and yield prominent and consistent policy resulting in impactful change. To achieve global impact, research priorities that address multi-disciplinary social, environmental, and clinical perspectives must be underpinned by unified approaches that maximize public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.